Gilead Viread Adds Boxed Warning Regarding Hepatitis B Co-Infection
This article was originally published in The Pink Sheet Daily
Patients co-infected with HBV and HIV should be monitored for hepatic problems “for at least several months” if they discontinue Viread treatment. Labeling update also includes precautions about interactions with Abbott’s Kaletra and Bristol’s Reyataz.
You may also be interested in...
Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.
Pink Sheet reporters and editor discuss the issues surrounding an FDA warning letter on Dsuvia promotion, an expected jump in CDER coronavirus-related workload, and a study of refuse-to-file actions.
Pink Sheet reporters and editor discuss the latest coronavirus vaccine news, CMS’ effect on the future of aducanumab, as well as new assessment goals for PDUFA VII.